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Lack of complex I is associated with oncocytic thyroid tumours
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Oncocytic tumours are characterised by hyperproliferation of mitochondria. We immunohistochemically analysed all enzymes of the
oxidative phosphorylation system in 19 oncocytic thyroid tumours. A specific lack of complex I was detected, which was expressed at
o5% of the level determined in surrounding non-cancerous tissue.
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Oncocytic tumours and oncocytomas are benign or malignant
tumours consisting of oxyphilic cells, characterised histologically
by a fine granular eosinophilic cytoplasm and an increase in the
number of mitochondria ultrastructurally (Tallini, 1998). Although
oncocytic tumours are most frequently found in the thyroid gland,
kidney and salivary glands, they have also been reported in various
other organs, such as the brain (Gallina et al, 2006) and the skin
(Jih et al, 2004).
An association between mitochondrial DNA (mtDNA) muta-
tions and oncocytic thyroid tumours was reported in several
studies (Tallini et al, 1994; Maximo et al, 2002; Bonora et al, 2006).
A study on 45 oncocytic thyroid tumours identified potentially
pathogenic mutations in subunits of complex I (NADH-ubiqui-
none oxidoreductase) in 53% of the investigated samples
(Gasparre et al, 2007). However, the effects of the observed
mutations on complex I enzyme activity and protein content have
not been shown particularly for the remaining cases in which clear
evidence for complex I deficiency could not be shown. In contrast,
we identified a loss of complex I enzyme activity and protein in
100% of renal oncocytomas (Mayr et al, 2008). We hypothesised
that thyroid oncocytomas would exhibit a similar deficiency.
In this study, we investigated oncocytic thyroid tumours by
immunohistochemical staining to elucidate changes in the
mitochondrial energy metabolism in this tumour.
MATERIALS AND METHODS
Patients
Human oncocytic thyroid tumour (n¼19) and follicular thyroid
adenoma (n¼4) specimens were obtained from the Department of
Pathology, Paracelsus Private Medical University, Salzburg. The
study was carried out in accordance with the guidelines of the local
research ethics committee. Clinical parameters are summarised
in Table 1.
Immunohistochemical staining and analysis
For immunohistochemical staining, the following antibodies were
used: mouse monoclonal anti-complex I subunit NDUFS4 (1:1000;
Abcam, Cambridge, UK), mouse monoclonal anti-complex II
subunit 70kDa (1:3000; Mitosciences, Eugene, OR, USA), mouse
monoclonal anti-complex III subunit core 2 (1:1500; Mitosciences),
mouse monoclonal anti-complex IV subunit I (1:1000; Mitos-
ciences), mouse monoclonal anti-complex V subunit-a (1:2000;
Mitosciences) and mouse monoclonal anti-porin 31HL (1:3000;
Mitosciences). All antibodies were diluted in Dako antibody
diluent with background reducing components (Dako, Glostrup,
Denmark).
Tissue sections (5mm) were deparaffinised by three changes of
xylene, rehydrated in three changes of absolute 2-propanol
followed by heat-induced epitope retrieval in TE-T buffer (10mM
Tris pH 9.0, 1mM EDTA, 0.05% Tween 20) for 40min at 951C and
20min at room temperature. Sections were washed in distilled H2O
and equilibrated with phosphate-buffered saline containing 0.5%
Tween 20 (PBS-T pH 7.4). Staining was carried out using
the Envision Detection System (Dako) according to the manu-
facturer’s instructions followed by visualisation with diaminoben-
zidine (DAB) for 10min. Slides were counterstained with
haematoxylin.
To quantify differences in expression levels between tumour
tissue and the adjacent normal tissue, a scoring system for the
staining intensity (0: no staining; 1: weak staining; 2: moderate
staining; 3: strong staining) multiplied by the mean percentage of
immunopositive cells per high power fields was used. Quantifica-
tion was carried out independently by two different persons and
mean values are displayed.
Statistical analysis
For statistical analysis, the Wilcoxon matched-pair signed-rank
test was used for equality of distributions. The distribution of
complex I and complex V were compared between normal tissue
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sand the corresponding tumour tissue, respectively. The distribu-
tion of complex I was also compared to complex V in normal
tissue.
Analysis of mtDNA
Two 10mm sections were collected and deparaffinised by two
changes of xylene and absolute ethanol. After evaporation of
ethanol, tissues were treated with 200ml of PCRK (2mgml
 1
Proteinase K, 75mM Tris-HCl pH 8.8, 20mM (NH4)2SO4, 0.01%
Tween 20) at 601C for 24h followed by 951C for 10min. Sequence
analysis of the mtDNA was carried out as described previously
(Mayr et al, 2008).
RESULTS
Immunohistochemical staining
Oncocytic thyroid tumour cells were negative or greatly reduced
for the complex I subunit, NDUFS4, when compared with the
surrounding non-cancerous tissue in all investigated specimens
(Figure 1). Immunopositivity for complex II subunit 70kDa,
complex III subunit core 2, complex IV subunit I, complex V
subunit-a and the mitochondrial membrane protein porin was
increased in all tumour samples compared with adjacent
normal tissue (Figure 1). These changes were detected in all 17
oncocytic adenomas and the two cases of oncocytic thyroid
carcinomas. Follicular thyroid adenomas showed substantial
staining for all respiratory chain enzymes and porin
(Supplementary Figure 1).
Table 1 Clinical parameters of the patients with oncocytic thyroid
tumours
Parameter Determined Values: mean (range)
Age 19/19 55.6 years (27.6–83.8)
Gender 19/19
Male 3/19
Female 16/19
Diagnosis 19/19
Adenoma 17/19
Carcinoma 2/19
Tumour size 19/19 2.6cm (1–5.3)
Endocrine situation 18/19
Hypothyroid 1/18
Euthyroid 14/18
Hyperthyroid 3/18
Goitre 15/19
Yes 15/15
No 0/15
Immune thyroiditis 16/19
Yes 4/16
No 12/16
100  m 100 m
100 m 100 m
100 m 100 m
Figure 1 Representative immunohistochemical staining of all respiratory chain enzyme complexes and porin of an oncocytic thyroid adenoma.
(A) Positive staining for complex I subunit NDUFS4 in normal thyroid tissue (upper part) and immunonegative staining in oncocytic tumour tissue (lower
part). (B–E) Increased expression of respiratory chain complex II subunit 70kDa (B), complex III subunit core 2 (C), complex IV subunit I (D) and complex
V subunit-a (E) in oncocytic tumour compared with adjacent normal tissue. (F) Immunohistochemical staining of porin reveals the characteristic
upregulation of mitochondria in oncocytic tumour cells compared with normal thyroid tissue.
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All investigated oncocytic thyroid tumours showed a significant
downregulation of 95% of the complex I subunit NDUFS4, when
compared with the adjacent normal tissue (Po0.0001; Figure 2).
Complex V subunit-a showed significant upregulation of 40%
(Po0.0003) in the tumour tissue (Figure 2). There was no
significant difference in normal tissue between complex I and
complex V (P¼1.000). Loss of complex I staining was independent
of clinical features, such as endocrine situation, tumour size and
histology of the tumour tissues.
Follicular thyroid adenomas showed no statistically significant
difference between complex I and complex V staining in the
tumour tissues, compared with the adjacent normal tissue
(Supplementary Figure 2).
Mutation analysis of the mitochondrial genome
All seven mitochondrially encoded complex I subunits were
sequenced in 18 oncocytic thyroid tumours. Disruptive mutations
were found in the complex I genes ND1, ND4, ND4L, ND5 and
ND6. Six cases harboured frameshift mutations (3571_3572insC,
10477delT/10952_10953insC, 13235_13236insT, 14339_14340insA,
14603_14604insT), one case of a nonsense mutation (12539G4A)
and three cases of mutations causing amino-acid changes in highly
conserved domains (3392G4A, 3917A4G and 3946G4A). In
eight cases, no potentially pathogenic mutation was found.
DISCUSSION
Here, we provide strong evidence for an association between
specific loss of respiratory chain complex I and oncocytic thyroid
tumours. Mutations of mtDNA had previously been identified in
oncocytic thyroid tumours; 26.7% of specimens showed disruptive
mutations. Additional 26.7% had potentially deleterious missense
mutations in one of the seven mitochondrial genes coding for
subunits of complex I (Gasparre et al, 2007). Similar results were
obtained in our samples, where 33% had frameshift mutations, 6%
stop mutations and 17% potentially pathogenic point mutations.
We cannot exclude mutations in one of the 39 nuclear-encoded
subunits. An earlier study has already reported heterozygous
mutations in GRIM-19 (Maximo et al, 2005), a subunit of
mitochondrial complex I, which is also necessary for assembly.
On account of the heterogeneous composition of thyroid tumours,
it is difficult to prepare pure tumour homogenates for enzyme
measurements or western blot analysis. Gasparre et al (2007)
were, therefore, not able to report biochemical results of their
specimens. It is known from cell culture studies (Hofhaus
and Attardi, 1993) and from patients with complex I defects
(Ugalde et al, 2004a) that severe mutations in different subunits of
complex I result in reduced stability or incomplete assembly of the
enzyme complex. Moreover, non-mutant subunits of complex I
exhibit variable stability (Ugalde et al, 2004b). For example, the
NDUFS4 subunit is particularly unstable and its stability depends
on the presence of the preassembled complex I. Because of this
instability of unassembled NDUFS4, we used immunohistochem-
ical staining with an NDUFS4 antibody as a measure of complex I
content.
Complex I is an integral component of different apoptotic
pathways (Ricci et al, 2004; Martinvalet et al, 2008). Thus,
deficiency of complex I could play a role in tumour formation
by interrupting apoptotic pathways. Besides its function as part of
the respiratory chain, complex I can be transformed to a potent
enzyme of reactive oxygen species (ROS) formation. It was shown
that the NDUFS1 subunit of complex I can be proteolytically
cleaved by caspase-3, which results in a truncated enzyme complex
disposed for ROS production (Ricci et al, 2004). In a second,
caspase-independent apoptotic pathway granzyme A specifically
cleaves subunit NDUFS3 of complex I. This again results in
increased generation of ROS, disruption of the mitochondrial
transmembrane potential and cell death (Martinvalet et al, 2008).
Lack of complex I, as identified in oncocytic thyroid tumours, may,
therefore, prevent tumour cells from undergoing apoptosis
through these pathways.
The clinical parameters shown in Table 1 are typical for the
diagnosis oncocytoma and the complex I deficiency was indepen-
dent of age, gender, tumour size, histology and endocrine
situation. All investigated thyroid oncocytomas showed complex
I deficiency and most had a benign clinical course; however, 2 of
the 19 tumours in this study were carcinomas. Renal oncocytoma,
another type of oncocytic tumour with a benign course, was
recently found to be associated with complex I deficiency
(Gasparre et al, 2008; Mayr et al, 2008). The oncocytic tumour
cell line XTC.UC1, which is derived from a metastasis of a Hu ¨rthle
cell carcinoma, shows both an insertion mutation in the gene
encoding ND1 subunit of complex I and a reduction in complex I
activity (Bonora et al, 2006). Ishikawa et al (2008) reported
complex I deficiency caused by mutations in the ND6 gene of
complex I in non-oncocytic mouse lung tumours. Interestingly,
these mutations increased the metastatic potential of the tumours
(Ishikawa et al, 2008), whereas complex I deficiency in oxyphilic
tumours does not seem to be associated with metastasis. For that
reason, complex I deficiency is not considered as a specific feature
of benign oncocytic tumours.
To establish that isolated complex I deficiency is a characteristic
of oncocytic thyroid tumours, but not a general feature of
thyroid tumours, we analysed four follicular thyroid adenoma
samples. In contrary to oncocytomas, follicular thyroid
adenomas displayed no significant reduction of respiratory chain
enzymes.
Loss of complex I was found in all investigated oncocytic
thyroid tumour samples. Because of the strict dependence of
such tumours on glycolytic metabolism, this unique feature
could enable the development of novel targeted therapies for this
disease.
ACKNOWLEDGEMENTS
This study was supported by the Salzburger Krebshilfe, the
Vereinigung zur Fo ¨rderung der pa ¨diatrischen Forschung und
50
100
150
200
250
300
S
c
o
r
i
n
g
Normal tissue 
CI
Tumour tissue 
CI
Normal tissue 
CV
Tumour tissue 
CV
Figure 2 Score values for staining intensity of immunopositive cells in
normal and tumour tissues of 19 patients with oncocytic thyroid tumours
with complex I and complex V antibodies, respectively.
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